AGP Picks
View all

Thyrogen market seen reaching $1.74M by 2030

Nov. 12, 2026
Thyrogen market seen reaching $1.74M by 2030
By AI, Created 17:15 UTC, Nov 12, 2026, AGP -

The Business Research Company says the Thyrogen market grew to $1.17 million in 2025 and is projected to reach $1.74 million by 2030, driven by rising thyroid cancer cases, personalized medicine and broader use of patient-friendly diagnostic methods. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Thyrogen is used to help detect residual thyroid cancer without forcing patients to stop thyroid hormone therapy. - The market’s projected growth signals rising demand for more precise, less disruptive thyroid cancer diagnostics and follow-up care. - Growth also points to broader adoption of personalized medicine in endocrine oncology.

What happened: - The Business Research Company said the global Thyrogen market reached $1.17 million in 2025. - The market is projected to rise to $1.27 million in 2026. - The report forecasts the market will reach $1.74 million by 2030. - The company published the outlook in its report, Thyrogen Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035.

The details: - Thyrogen, also known as thyrotropin alfa, is a synthetic analogue of thyroid-stimulating hormone. - The drug helps stimulate the thyroid to absorb radioactive iodine for diagnostic scans and treatment. - Thyrogen supports testing and treatment after thyroid gland removal without requiring thyroid hormone withdrawal. - The report links near-term growth to thyroid hormone withdrawal avoidance, rising thyroid cancer cases, increased hospital-based diagnostic imaging, clinical validation of TSH stimulation, and reliance on radioiodine scans. - The report links longer-term growth to expanded thyroid cancer screening, better diagnostic accuracy, more outpatient diagnostic centers, greater patient focus on quality of life, and higher investment in endocrine oncology. - The report highlights growing use of thyroid cancer surveillance tools, patient-friendly diagnostic methods, radioiodine-based diagnostics, post-thyroidectomy care, and improved endocrine cancer outcomes. - The report says North America held the largest share of the global market in 2025. - The report says Asia-Pacific will be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report says its 2026 editions include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology analysis and future trend analysis. - Download the free sample report - View the full market report

Between the lines: - The forecast suggests Thyrogen demand is being pulled by both clinical necessity and a shift toward less burdensome cancer testing. - The regional split implies mature uptake in North America and more room for expansion in Asia-Pacific as diagnostics and oncology spending rise. - The personalized medicine trend matters because Thyrogen fits workflows that aim to tailor care more closely to individual thyroid cancer patients. - The report cites American Cancer Society projections of about 44,020 new thyroid cancer cases in the U.S. in January 2024, up from 43,720 in 2023. - The same projection included about 2,170 deaths in the U.S., with 990 among men and 1,180 among women. - The Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022, including seven cancer drugs.

What's next: - The market’s next phase will likely depend on how quickly thyroid cancer screening, outpatient diagnostics and radioiodine-based care expand. - The report expects continued gains through 2030 as healthcare systems emphasize earlier detection and quality-of-life improvements. - Monitoring Asia-Pacific adoption will be key for understanding where the fastest growth materializes.

The bottom line: - Thyrogen is a small but growing niche tied to thyroid cancer care, and the market outlook points to steady expansion through 2030.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa News Guide

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.